A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897 in Healthy Adults
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to evaluate the safety, tolerability and pharmacokinetics of an
extended half-life anti-respiratory syncytial virus (RSV) monoclonal antibody compared to
placebo when administered to healthy adult participants.